Allogeneic vs. autologous intra-articular mesenchymal stem cell injection within normal horses: Clinical and cytological comparisons suggest safety.
Authors: Colbath A C, Dow S W, Hopkins L S, Phillips J N, McIlwraith C W, Goodrich L R
Journal: Equine veterinary journal
Summary
# Editorial Summary: Allogeneic versus Autologous Stem Cell Injections in Equine Joints Mesenchymal stem cell therapy has become increasingly popular in equine practice, but the requirement for autologous cell harvesting limits availability and introduces individual variation in cell quality. Colbath and colleagues conducted a randomised controlled trial comparing the safety profile of pooled-allogeneic bone marrow-derived mesenchymal stem cells (BMDMSCs) against autologous BMDMSCs by injecting 10 million cells into contralateral metacarpophalangeal joints in eight horses, then monitoring lameness (both subjective and via Lameness Locator™), joint effusion, and synovial fluid markers—including prostaglandin E2, C-reactive protein, and nucleated cell counts—over 14 days. The researchers detected no clinically or statistically significant differences between treatments across any parameter measured, suggesting allogeneic cells provoked comparable local and systemic responses to autologous cells in normal joints. Whilst this study deliberately excluded assessment of therapeutic efficacy, the safety equivalence demonstrated opens the door to larger studies investigating whether allogeneic BMDMSCs could provide a practical, 'off-the-shelf' alternative to autologous cell therapy, potentially reducing treatment delays and standardising cell quality across clinical applications. Practitioners should note, however, that these findings are specific to injection into non-inflamed joints; further work is needed to determine whether this safety profile holds in diseased tissue or acute injury scenarios.
Read the full abstract on PubMed
Practical Takeaways
- •Allogeneic mesenchymal stem cells appear safe for intra-articular use in horses and could offer practical advantages (off-the-shelf availability, reduced processing time) over autologous harvesting
- •Normal joint response is comparable between allogeneic and autologous preparations, though efficacy in diseased joints remains to be established
- •Larger equivalence studies are needed before allogeneic BMDMSCs can be recommended as a clinical alternative in therapeutic applications
Key Findings
- •No difference detected in clinical parameters (lameness, joint circumference, effusion) between autologous and pooled-allogeneic BMDMSC injections in normal equine joints
- •No difference in synovial fluid cytological markers (nucleated cell count, differential counts, total protein, PGE2, and CRP) between treatment groups across all timepoints (6–336 hours post-injection)
- •Allogeneic BMDMSCs demonstrated safety comparable to autologous BMDMSCs in non-inflamed joints
- •Study was designed to assess safety and tolerance in normal joints only, not efficacy for musculoskeletal disease